Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism.
Laura M TsujikawaLi FuShovon DasChristopher HallidayBrooke D RakaiStephanie C StotzChristopher D SarsonsDean GilhamEmily DazeSylwia WasiakDeborah StuderKristina D RinkerMichael SweeneyJan O JohanssonNorman C W WongEwelina KulikowskiPublished in: Clinical epigenetics (2019)
Apabetalone suppressed gene expression of VI mediators in monocytes and endothelial cells by inhibiting BET-dependent transcription induced by multiple inflammatory stimuli. In CVD patients, apabetalone treatment reduced circulating levels of VI mediators, an outcome conducive with atherosclerotic plaque stabilization and MACE reduction. Inhibition of inflammatory and adhesion molecule gene expression by apabetalone is predicted to contribute to MACE reduction in the phase III BETonMACE trial.
Keyphrases
- gene expression
- phase iii
- end stage renal disease
- newly diagnosed
- endothelial cells
- dna methylation
- oxidative stress
- ejection fraction
- chronic kidney disease
- clinical trial
- peritoneal dialysis
- prognostic factors
- open label
- patient reported outcomes
- immune response
- study protocol
- double blind
- peripheral blood
- vascular endothelial growth factor
- patient reported
- placebo controlled
- high glucose